Alan Breier

Dr. Alan Breier is Karuna’s Chief Clinical Advisor and Chair of it’s Scientific Advisory Board. Dr. Breier previously was the Chief Medical Officer at Eli Lilly and is currently Professor of Psychiatry and Vice Chair for Clinical Research at Indiana University School of Medicine and Chief of the Psychotic Disorders Program. He was a member of Lilly Research Laboratories’ policy committee and the company’s senior management council. Previously, Dr. Breier was a clinical research fellow at Eli Lilly, product team leader for the antipsychotic drug Zyprexa and Vice President of Pharmaceutical Products at Eli Lilly. Prior to joining Eli Lilly, Dr. Breier was Chief of the Section of Clinical Studies at the NIMH Intramural Research Program and prior to that the Chief of the Outpatient Research Program at the Maryland Psychiatric Research Center.

Dr. Breier received a bachelor’s degree from University of Toledo and an M.D. from the University of Cincinatti. He has published over 250 scientific articles and is the recipient of several awards.